정보마당

No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

8/4

Pathos AI

Alphamab Oncology

JSKN016

HER3×TROP2 bispecific ADC
(ex China rights)

Oncology

TNBC

Phase 3

2,218

2

8/4

Pathos AI

AstraZeneca

AZD4241

ERα PROTAC

Oncology

ER+/HER2- BC

Preclinical

n/d

3

8/5

Maruishi Pharmaceutical

Adneuris Therapeutics

Cebranopadol

Dual‑NMR agonist (NOP/MOP)
(Korea, Japan rights)

Neurology

Acute pain

Phase 3

35+

4

8/5

Eton Pharmaceuticals

Auson Pharmaceuticals

ASN-001

ADRB blocker
(US rights)

Dermatology

Moderate Infantile Hemangiomas

Phase 2/3

n/d

5

8/6

Ono Pharma

Mediar Therapeutics

-

fibrosis-focused research platform

Inflammatory diseases

Fibro-inflammatory Diseases

Discovery

n/d

6

8/10

Sobi

Innate Pharma

Lacutamab

αKIR3DL2 mAb

Oncology

Cutaneous T cell lymphoma (CTCL); Sézary syndrome

Phase 2

115

7

8/10

BeOne Medicines

Revolution Medicines

Daraxonrasib

Zoldonrasib

Elironrasib

RMC-5127

RAS(ON) multi-selective inhibitor

RAS(ON) G12D inhibitor

RAS(ON) G12C inhibitor

RAS(ON) G12V inhibitor

(Asia rights ex Korea, Japan combo w/ Daraxonrasib or Zoldonrasib)

Oncology

Oncology

Oncology

Oncology

Pancreatic cancer

NSCLC

NSCLC

Solid tumors; PDAC, CRC, NSCLC

FDA Approved

Phase 3

Phase 3

Phase 1

n/d

8

8/10

Tanabe Seiyaku

Energenesis Biomedical

ENERGI-F703DFU

AMPK activator
(Taiwan NDA‑focused joint development)

Metabolic disorders

Diabetic foot ulcers

Phase 3

n/d

9

8/10

Oculis Holding

Accure Therapeutics

Privosegtor(ACT-01)

ACT-02

Peptoid SGK2/FOXO3 activator

n/d

Immunology

Neurology

Multiple sclerosis

Parkinson’s disease

Phase 3

Preclinical

n/d

10

8/12

PTC Therapeutics

Sangamo Therapeutics*

Isaralgagene civaparvovec
 (ST-920)

AAV2/6‑mediated GLA gene therapy

Metabolic disorder

Fabry Disease

FDA under review

211

11

8/14

EMD Serono

Werewolf Therapeutics

‘INDUCER’ platform

‘INDUKINE’ platform

Tumor‑activated IL‑2 prodrug (protease‑cleavable)

Tumor‑conditional cytokine agonist (IL‑2/IL‑15 variants)

Oncology

Oncology

Solid tumor

Solid tumor

Preclinical

Preclinical

33

12

8/17

Eli Lilly

OmniAb

-

Ion channel program

n/d

n/d

Discovery

370

13

8/18

Leo Pharma

Tanabe Pharma

Dersimelagon

Melanocortin‑1 receptor agonist

Metabolic disease

Erythropoietic protoporphyria

NDA Submitted

435+

14

8/19

Genentech

(Roche)

IDEAYA Biosciences

Genentech: RG6620(KRAS G12D inhibitor)

IDEAYA: IDE892(PRMT5 inhibitor)

Collaboration: RG6620+ IDE892 combination

Oncology

MTAP‑deleted/KRAS G12D‑mutant PDAC

IND‑enabling/ ready

n/d

15

8/19

NeoImmuneTech

Tolerance Bio

Efineptakin alfa

(NT-I7)

IL-7 fusion protein
(USA, EU rights)

Immunology

HIV immunological non‑response

Phase 1

260

16

8/19

BioArctic

Mesenkia Therapeutics

BioArctic: BrainTransporter™(BBB‑shuttling transporter for antibody brain delivery)

Mesenkia: ‘KITAIbodies’ platform(Glioblastoma‑targeting antibody platform; HVEM‑directed)

Oncology

Glioblastoma

Preclinical

n/d

17

8/20

Chong Kun Dang

Kiora Pharmaceuticals

KIO-301

Optogenetic molecular photoswitch

Ophthalmology

Retinitis pigmentosa

Phase 1/2

n/d

18

8/24

Genentech

(Roche)

Hanmi Pharmaceutical

HM17321

Non‑incretin UCN2 receptor agonist (ex Korea rights)

Metabolic disorder

Obesity

Phase 1

2,490

19

8/25

Sentivera**

Haisco Pharmaceutical

n/d

n/d

Inflammation disease

Type 2 inflammation

Preclinical

1,536

20

8/26

SK Biopharmaceuticals

Biohaven

Opakalim

(BHV‑7000)

Kv7.2/7.3 heteromeric ion channel activator (selective; GABA‑sparing)

Neurology

Focal epilepsy

Phase 2/3

795

21

8/28

Genentech

(Roche)

DualityBio

‘Dupac’ platform

Non‑topoisomerase payloads (mRNA translation inhibitor / ecteinascidin derivative)

Oncology

ADC‑resistant solid tumors

Discovery

1,045

22

8/28

Create Medicines

WestGene Biopharma

CRT-403

CRT-401

RetroT‑enabled CD19×BCMA

CD19xBCMA In vivo CAR-T

HER2×TROP2 In vivo CAR-T

CD19×BCMA In vivo CAR-T

Immunology

Oncology

Immunology

Autoimmune disease

Epithelial cancer

Autoimmune disease

Preclinical

Preclinical

Preclinical

n/d

23

8/28

Teva Pharmaceuticals

BioXcel Therapeutics

BXCL501

Selective alpha‑2 adrenergic receptor agonist

Neurology

Schizophrenia, bipolar I/II disorder

FDA Under review

125

24

8/31

Cipla

Sino Biopharmaceutical

Rolditamig deuderuxtecan

(TQB2102)

HER2xCD16A BsAb‑ADC

Oncology

HER2-expressing cancers; HER2-low advanced BC

Phase 1

123

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

8/3

Curium US

Lantheus holdings

Definity

Pylarify

Neuraceq

Microbubble US contrast agent

18F‑PSMA PET radioligand

18F‑amyloid‑β PET radioligand

Others

Others

Others

Cardiovascular diagnostics

Prostate cancer diagnostics

Alzheimer’s disease diagnostics

Marketed

Marketed

Marketed

8,000

2

8/6

Tarsus Pharmaceuticals

Alkeus Pharmaceuticals

Gildeuretinol
(ALK-001)

Retinol dimerization inhibitor

Ophthalmology

Stargardt disease

Phase 3

800

3

8/10

Jazz Pharmaceutical

Actio Biosciences

ABS-1230

KCNT1 inhibitor

Neurology

KCNT1+ Epilepsy

Phase 1/2

1,320

4

8/14

IASO Biotechnology

MediSix Therapeutics

‘PEBL’ platform

IASO107

PEBL T‑cell fratricide prevention platform

CD7 CAR‑T

-

Oncology

-

ALL, AML, Lymphoma

-

Phase 1

n/d

5

8/14

Redx Pharma*

Fibrx Therapeutics**

RXC008

Zelasudil
(RXC007)

n/d

GI‑restricted pan‑ROCK inhibitor

Selective ROCK2 inhibitor

DDR inhibitor

Immunology

Immunology

Immunology

Fibrostenotic Crohn’s disease

Idiopathic pulmonary fibrosis

Fibrosis; kidney, lung and liver

Phase 1

Phase 2

Preclinical

n/d

6

8/17

Slate Medicines*

Fulcrum Therapeutics

SLTE‑1009

SLTE‑2100

PACAP/VIP dual‑targeting mAb

CGRPxPACAP/VIP BsAb

Neurology

Neurology

Migraine prophylaxis

Migraine prophylaxis

Phase 1

Preclinical

n/d

7

8/18

BioMarin

Alesta Therapeutics

ALE1

Undisclosed novel PPi regulating target inhibitor

Metabolic bone disease

Hypophosphatasia

Phase 1/2a

490

8

8/21

Ambros Therapeutics*

Werewolf Therapeutics

Neridronate

Farnesyl pyrophosphate synthase (FPPS) inhibitor / osteoclast inhibitor

Neurology

Complex regional pain syndrome type 1 (CRPS‑1)

Phase 3

150+

9

8/31

Eli Lilly

Merida Biosciences

MER511

TSHR-IgG Fc fusion protein

Immunology

Ophthalmology

Graves' disease

Thyroid eye disease

Phase 1

Phase 1

2,875